Where Shoppers Are Now
Private label's share gains over the inflation cycle were supposed to reverse once prices stabilised. They have not. NIQ data for Western Europe puts retailer-brand share near 30 percent. In the US the figure sits above 21 percent. Both numbers reflect a pattern that commercial teams should treat as structural rather than cyclical: shoppers who traded into private label during the 2022 to 2024 inflation period largely stayed there.
The reason is not purely price. Shoppers who moved to retailer brands found that quality had improved significantly. Retailers invested in product development during the inflation years precisely because high shelf prices made the quality gap between national brands and their own ranges smaller and more visible. That investment is now showing up in share data that has not unwound.
The macroeconomic backdrop keeps the pressure on. Five major European trade associations, including FoodDrinkEurope and EuroCommerce, issued a joint warning in May 2026 that Middle East supply disruptions are already pushing input costs higher across fertilisers, energy, packaging, and logistics (Just Food). A fresh inflation wave would reset the value equation in private label's favour again, at a moment when retailer brands are already better quality than they were in 2022.
Mondelez's Q1 2026 results add texture. CEO Dirk Van de Put described European consumer confidence as "stable but fragile" and US confidence as "quite low" with further deterioration expected (ConfectioneryNews). When shoppers describe themselves as anxious about spending, they look harder at the shelf. Private label is usually what they find.
Private Label Pressure in Consumer Health
Private label pressure is not confined to food. Haleon's Q1 2026 trading statement flagged ongoing private-label pressure in mainstream pain relief, with Pain Relief organic growth at -0.3% on £654 million in sales (Haleon IR). Advil outperformed in North America behind a specific brand campaign, but the broader category was soft and private label was named as part of the drag.
Reckitt reported Core LFL net revenue growth of only 1.3% in Q1 2026, with the underlying figure excluding seasonal OTC at 3.1% (Reckitt IR). The pattern across both companies points to the same dynamic: in categories where shopper trust in product performance is high enough, and where the active ingredient is identical between national brand and own-label, private label wins on price every time the shopper feels financial stress.
Consumer health was slower to see retailer brand penetration than food because shoppers historically believed there was a quality or safety difference between branded and own-label medicines. That belief is weakening. Pharmacies and major grocery retailers have invested in own-label health ranges, and the regulatory environment guarantees identical actives. For Haleon, Reckitt, and the OTC brands that sit below their scale, this is a structural headwind, not a one-quarter noise event.
Implications
Three things are worth acting on now.
First, the price gap between your brand and the retailer's premium own-label alternative is the number that matters most. Not your gap to the value PL line. Shoppers in 2026 are comparing your national brand to the premium tier, and in many categories the gap has narrowed to a point where your brand needs a stronger quality or functional story to hold its ground.
Second, if you supply private label alongside your branded business, the East Coast Bakehouse deal is a reminder that the retailer's investment in own-label supply is accelerating. Understand which of your capacity is exposed to retailer brand competition and whether your innovation pipeline is ahead of or behind what the retailer is planning for its own range.
Third, consumer confidence data from Mondelez and the European trade body inflation warning together suggest the conditions that kept private label elevated are not going away. Danone's FY 2025 results showed volume and mix finally outpacing pricing for a major European food company, with €27.3 billion in sales up 4.5% like-for-like and volume/mix at +2.7% versus pricing at +1.8% (Danone IR). That mix engine only works if the national brand has a clear reason to exist above the premium PL line. Build that reason now, before the next inflation wave makes the conversation harder.